## **Theodoros Kassimatis**

## List of Publications by Citations

 $\textbf{Source:} \ https://exaly.com/author-pdf/5406524/theodoros-kassimatis-publications-by-citations.pdf$ 

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

36
citations

11
h-index

38
ext. papers

444
ext. citations

364
h-index

6.9
avg, IF

L-index

#	Paper	IF	Citations
36	A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial. <i>Trials</i> , <b>2017</b> , 18, 255	2.8	56
35	Statins and prostate cancer: molecular and clinical aspects. European Journal of Cancer, 2011, 47, 819-30	<b>3</b> 7.5	52
34	Anaemia, microcytosis and sirolimusis iron the missing link?. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1667-75	4.3	37
33	A fatal case of paraquat poisoning following minimal dermal exposure. Renal Failure, 2007, 29, 375-7	2.9	29
32	Impaired desensitization of a human polymorphic DB-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. <i>Cell Communication and Signaling</i> , <b>2011</b> , 9, 5	7.5	26
31	Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples. <i>EBioMedicine</i> , <b>2019</b> , 41, 571-583	8.8	20
30	Statins in chronic kidney disease and kidney transplantation. <i>Pharmacological Research</i> , <b>2014</b> , 88, 62-73	10.2	16
29	The role of statins in chronic kidney disease (CKD): friend or foe?. <i>Pharmacology &amp; Therapeutics</i> , <b>2009</b> , 122, 312-23	13.9	15
28	Chronic exposure of human glomerular epithelial cells to high glucose concentration results in modulation of high-affinity glucose transporters expression. <i>Renal Failure</i> , <b>2007</b> , 29, 353-8	2.9	13
27	Dyslipidemia, statins, and CKD patientsToutcomes - review of the evidence in the post-sharp era. Journal of Nephrology, <b>2012</b> , 25, 460-72	4.8	12
26	UK renal transplant outcomes in low and high BMI recipients: the need for a national policy. <i>Journal of Nephrology</i> , <b>2020</b> , 33, 371-381	4.8	12
25	Long-term safety and efficacy of renin-angiotensin blockade in atherosclerotic renal artery stenosis. <i>International Urology and Nephrology</i> , <b>2012</b> , 44, 1451-9	2.3	8
24	Outcomes in Third and Fourth Kidney Transplants Based on the Type of Donor. <i>Transplantation</i> , <b>2019</b> , 103, 1494-1503	1.8	8
23	Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1012-1026	8.7	8
22	Duration of delayed graft function and outcomes after kidney transplantation from controlled donation after circulatory death donors: a retrospective study. <i>Transplant International</i> , <b>2019</b> , 32, 635-6	435	7
21	COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity. <i>Transplantation Proceedings</i> , <b>2021</b> , 53, 1160-1168	1.1	7
20	Chronic histological changes in deceased donor kidneys at implantation do not predict graft survival: a single-centre retrospective analysis. <i>Transplant International</i> , <b>2019</b> , 32, 523-534	3	5

## (2007-2015)

19	Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: a meta-analysis. <i>Transplant International</i> , <b>2015</b> , 28, 330-4	403	4
18	Transcription factor Sp1 expression is upregulated in human glomerulonephritis: correlation with pSmad2/3 and p300 expression and renal injury. <i>Renal Failure</i> , <b>2010</b> , 32, 243-53	2.9	4
17	Rosuvastatin in patients undergoing hemodialysis. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 93; author reply 94-5	59.2	4
16	Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation. <i>Renal Failure</i> , <b>2014</b> , 36, 1310-6	2.9	3
15	Individualization of theophylline infusion rate on the basis of a nonlinear compartmental pharmacokinetic model. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>1997</b> , 22, 265-76	2.7	3
14	Hypoperfusion warm ischaemia time in renal transplants from donors after circulatory death. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 1628-1634	4.3	3
13	Successful medical treatment of emphysematous pyelonephritis in chronic hemodialysis. <i>Hemodialysis International</i> , <b>2015</b> , 19, E54-8	1.7	2
12	Bilirubin as a predictor of albuminuria and atherosclerosis in type 2 diabetic patients: misleading data. <i>Kidney International</i> , <b>2009</b> , 75, 862; author reply 862-3	9.9	2
11	Statins in patients with chronic kidney disease: a double-edged sword?. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1679; author reply 1680	15.1	2
10	The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT II)dosage monitoring. <i>Nephrology Dialysis Transplantation</i> , <b>2006</b> , 21, 3341-2	4.3	2
9	Recurrent flushing in a hemodialysis patient. Seminars in Dialysis, 2006, 19, 558-9	2.5	2
8	Acute renal failure and hypercalcaemia: sarcoidosis may be the culprit. Renal Failure, 2007, 29, 111-2	2.9	1
7	New hope for chronic kidney disease patients after the JUPITER trial: myth or reality?. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 529	15.1	О
6	Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. <i>Journal of Cellular and Molecular Medicine</i> , <b>2006</b> , 10, 838-851	5.6	O
5	The implications of donor-recipient size mismatch in renal transplantation. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 2037-2051	4.8	O
4	Paricalcitol for reduction of albuminuria in diabetes. <i>Lancet, The</i> , <b>2011</b> , 377, 635, author reply 636-7	40	
3	Fatal arteriovenous graft infection in a diabetic haemodialysis patient. <i>Emergency Medicine Journal</i> , <b>2008</b> , 25, 240	1.5	
2	Facial and left arm swelling in a hemodialysis patient. <i>Seminars in Dialysis</i> , <b>2007</b> , 20, 269-70	2.5	

CVD in CKD: Focus on the Dyslipidemia Problem **2014**, 67-91